New Rochelle, NY—RNA interference (RNAi) represents an innovative new strategy for using small RNA molecules to silence specific genes associated with disease processes, and a series of review articles describing the state-of-the-
At least six clinical trials using RNA interference (RNAi) have been approved, “with many more coming down the pipeline,” according to the Editorial (http://www.liebertonline.com/
The excitement surrounding RNAi and the two main approaches to delivering RNA-based therapeutics—
Traditionally, gene therapy has focused on supplying a normal copy of a faulty gene, whereas RNAi turns off a problematic gene. These contrasting approaches share some of the same techniques and challenges, including delivery of a therapeutic gene or siRNA into cells. Human Gene Therapy will publish a series of review papers in four consecutive issues focusing on a range of topics related to therapeutic applications of small RNAs. The series begins in the January issue with a paper entitled, “Behind the Scenes of a Small RNA Gene-Silencing Pathway,” by Gregory Ku, MD, PhD, and Michael McManus, PhD, from the University of California, San Francisco, which presents the current understanding of microRNA mechanisms of action and the potential for applying this knowledge to the development of RNAi-based treatments.
In the review by Anton McCaffrey, PhD, and Rebecca Marquez, MA, entitled, “Advances in Micro-RNAs: Implications for Gene Therapists,”
"The concept of using RNA as a therapeutic product is quite attractive and adds an important new dimension to the field of nucleic acid based therapeutics including gene therapy. Mark Kay, Associate Editor of Human Gene Therapy, has organized an exciting series of reviews summarizing the state of the art of this emerging field," says James M. Wilson, MD, PhD, Editor-in-Chief, and Head of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, in Philadelphia.
Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, is an authoritative peer-reviewed journal published monthly in print and online that presents reports on the transfer and expression of genes in mammals, including humans. Topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Tables of contents and a free sample issue may be viewed online.
Mary Ann Liebert, Inc., is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, and Cloning and Stem Cells. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 60 journals, books, and newsmagazines is available at www.liebertpub.com
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 www.liebertpub.com Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2110
# # #
Mary Ann Liebert, Inc., is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, and Cloning and Stem Cells. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide.